Oral smoothened inhibitors for Gorlin syndrome: A clinical review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38950707.
- Also identified by DOI 10.1016/j.jaad.2024.06.047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although smoothened inhibitors (SMOi) have demonstrated efficacy in the management of basal cell carcinoma, no guidelines are available on how to utilize SMOi in the treatment of Gorlin syndrome (GS). This review's objective is to assess the clinical response to SMOi in GS, provide practical guidance for clinicians, and identify areas for future research. Through comprehensive searches of previous publications and expert opinion, this review demonstrates that intermittent dosing of SMOi and daily dosing have similar efficacy. While the adverse events of SMOi may result in their discontinuation during treatment of GS, intermittent dosing may improve compliance.
Medical subject headings
- Basal Cell Nevus Syndrome
- Smoothened Receptor
- Skin Neoplasms
- Pyridines